Dishman Carbogen Amcis Ltd
DCALDishman Carbogen Amcis Ltd
DCAL
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -19.69 | 0.61 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.71 | 6.31 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Dishman Carbogen Amicis Limited is an India-based contract research and manufacturing services (CRAMS) company. The Company is engaged in the process of research and development to late-stage clinical and commercial manufacturing
Investor Presentation
View olderPeers
Compare with peersDivi's Laboratories Ltd
Syngene International Ltd
Aarti Pharmalabs Ltd
Vimta Labs Ltd
Brooks Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,739.82 | 1,740.48 | 2,112.42 | 2,088.06 | 1,950.48 | 2,184.11 | 2,440.69 | 2,643.98 | 2,639.91 | |||||||||
Raw Materials | 329.58 | 402.19 | 378.01 | 476.38 | 434.77 | 460.50 | 630.40 | 601.21 | 2,350.20 | |||||||||
| Power & Fuel Cost | 49.47 | 48.33 | 56.14 | 60.26 | 41.87 | 62.73 | 87.83 | 104.31 | ||||||||||
| Employee Cost | 596.02 | 625.40 | 714.64 | 762.27 | 872.91 | 981.49 | 1,029.86 | 1,208.16 | ||||||||||
| Selling & Administrative Expenses | 147.69 | 136.29 | 190.73 | 124.58 | 113.81 | 147.71 | 197.66 | 205.53 | ||||||||||
| Operating & Other expenses | 138.47 | 37.23 | 167.18 | 122.55 | 196.60 | 171.53 | 183.12 | 216.20 | ||||||||||
EBITDA | 478.59 | 491.04 | 605.72 | 542.02 | 290.52 | 360.15 | 311.82 | 308.57 | 289.71 | |||||||||
| Depreciation/Amortization | 213.50 | 211.42 | 240.38 | 282.87 | 307.94 | 307.59 | 280.72 | 310.86 | 308.05 | |||||||||
| PBIT | 265.09 | 279.62 | 365.34 | 259.15 | -17.42 | 52.56 | 31.10 | -2.29 | -18.34 | |||||||||
| Interest & Other Items | 49.01 | 48.83 | 56.55 | 61.95 | 47.61 | 56.81 | 85.69 | 119.97 | 132.59 | |||||||||
| PBT | 216.08 | 230.79 | 308.79 | 197.20 | -65.03 | -4.25 | -54.59 | -122.26 | -150.93 | |||||||||
| Taxes & Other Items | 70.65 | 76.22 | 98.46 | 38.69 | 100.10 | -22.26 | -24.79 | 31.19 | 23.10 | |||||||||
| Net Income | 145.43 | 154.57 | 210.33 | 158.51 | -165.13 | 18.01 | -29.80 | -153.45 | -174.03 | |||||||||
| EPS | — | 19.15 | 13.03 | 9.96 | -10.53 | 1.15 | -1.90 | -9.79 | -11.10 | |||||||||
| DPS | 1.20 | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||
| Payout ratio | — | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Dishman Carbogen Amcis Ltd | -22.33 | 0.61 | — |
| Divi's Laboratories Ltd | 99.17 | 11.69 | 0.50% |
| Syngene International Ltd | 66.62 | 7.98 | 0.15% |
| Aarti Pharmalabs Ltd | 25.78 | 3.18 | 0.49% |
Price Comparison
Compare DCAL with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Dishman Carbogen Amcis Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
HSBC Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8391% | Percentage of the fund’s portfolio invested in the stock 0.58% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 87/97 (-5) |
Motilal Oswal Nifty Microcap 250 Index Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0824% | Percentage of the fund’s portfolio invested in the stock 0.17% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 153/310 (-17) |
Bandhan BSE Healthcare Index Fund Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0005% | Percentage of the fund’s portfolio invested in the stock 0.10% | Change in the portfolio weight of the stock over the last 3 months 0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 74/102 (+5) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
DCAL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2019
Dividend/Share
₹0.20
Ex DateEx Date
Sep 12, 2019
Net profit of Dishman Carbogen Amcis reported to Rs 33.09 crore in the quarter ended September 2024 as against net loss of Rs 40.90 crore during the previous quarter ended September 2023. Sales rose 34.51% to Rs 789.04 crore in the quarter ended September 2024 as against Rs 586.59 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales789.04586.59 35 OPM %18.6510.37 - PBDT117.1741.83 180 PBT45.08-33.21 LP NP33.09-40.90 LP Powered by Capital Market - Live
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
Dishman Carbogen Amcis announced that the 17th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
On a consolidated basis, Dishman Carbogen Amcis reported net loss of Rs 77.57 crore in Q1 June 2024 as against net profit of Rs 17 crore in Q1 June 2023. Net sales declined 27.59% year-on-year to Rs 523.78 crore in Q1 June 2024. Net revenue was impacted mainly due to lower revenue in Switzerland and Netherlands. Pre-tax loss stood at Rs 77.56 crore in Q1 June 2024 as against pre-tax profit of Rs 29.49 crore in Q1 June 2023. EBITDA slumped 76.8% YoY to Rs 29.39 crore in Q1 June 2024. EBITDA margin stood at 5.6% in Q1 June 2024, lower than 17.5% in Q1 June 2023. This was primarily due to lower operating margins in its European subsidiaries, Carbogen Amcis AG and Carbogen Amcis BV. Factors contributing to this decline include delays in high-margin project realization, increased sales of lower-margin cholesterol products, and higher raw material costs. Additionally, the company incurred a larger operating loss in its French operations compared to the previous year. During the quarter, cost of goods sold (COGS) fell 59.4% YoY to Rs 66.35 crore while employee expenses rose 7.3% YoY to Rs 316.82 crore. Carbogen Amcis AG ' CRAMS revenue decreased by 39.6% YoY in Q1 FY25 primarily due to shifting of a major development project and deferment of shipment of a commercial batch to the next quarters. This had an impact of CHF 9.8 m in revenue and CHF 3.92 m in operating profit due to timing difference. Carbogen Amcis BV' Cholesterol and Vitamin D analogues revenue decreased by 16.4% YoY in Q1 FY25 primarily due to lower sales of Vitamin D analogs by 38%. This is expected to pick up in revenue in the remainder part of the year. DCAL India ' NCE APIs and Intermediates revenue increased by 114.5% YoY in Q1 FY25 primarily due to increase in commercial supplies from Bavla site after the EDQM clearance. DCAL India ' Quats & Generics revenue decreased by 20.4% YoY in Q1 FY25 primarily due to slow down in agrochemical sector, which is expected to pick up in the second half of the year. Dishman Carbogen Amcis is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies. The company has global presence with development and manufacturing sites in Switzerland, UK, France, Netherlands, India and China. Powered by Capital Market - Live
Piramal Enterprises Ltd, Redtape Ltd, Kaveri Seed Company Ltd and HEG Ltd are among the other losers in the BSE's 'A' group today, 14 August 2024.Dishman Carbogen Amcis Ltd crashed 11.40% to Rs 173.3 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 1.41 lakh shares were traded on the counter so far as against the average daily volumes of 87555 shares in the past one month.Piramal Enterprises Ltd tumbled 10.31% to Rs 884.1. The stock was the second biggest loser in 'A' group.On the BSE, 3.45 lakh shares were traded on the counter so far as against the average daily volumes of 72683 shares in the past one month.Redtape Ltd lost 8.07% to Rs 630.95. The stock was the third biggest loser in 'A' group.On the BSE, 6817 shares were traded on the counter so far as against the average daily volumes of 5678 shares in the past one month.Kaveri Seed Company Ltd shed 7.55% to Rs 1029.9. The stock was the fourth biggest loser in 'A' group.On the BSE, 12629 shares were traded on the counter so far as against the average daily volumes of 29328 shares in the past one month.HEG Ltd corrected 6.99% to Rs 2015.85. The stock was the fifth biggest loser in 'A' group.On the BSE, 21260 shares were traded on the counter so far as against the average daily volumes of 12450 shares in the past one month.Powered by Capital Market - Live
Net loss of Dishman Carbogen Amcis reported to Rs 77.57 crore in the quarter ended June 2024 as against net profit of Rs 17.00 crore during the previous quarter ended June 2023. Sales declined 27.59% to Rs 523.78 crore in the quarter ended June 2024 as against Rs 723.38 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales523.78723.38 -28 OPM %5.5316.85 - PBDT-1.5399.94 PL PBT-72.1229.49 PL NP-77.5717.00 PL Powered by Capital Market - Live
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Cholamandalam Financial Holdings Ltd leads gainers in ‘A’ group
Dishman Carbogen Q4 earnings effect: Shares plunge 12% in early trade, top losers on BSE
Dishman Carbogen declines 10% after Q4 loss widens
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 4.59%, vs industry avg of 4.51%
Decreasing Market Share
Over the last 5 years, market share decreased from 17.23% to 15.03%